Randomized phase III trial of carboplatin/paclitaxel alone (CP) or in combination with bevacizumab followed by bevacizumab (CPB) and secondary cytoreduction surgery in platinum-sensitive recurrent ovarian cancer: GOG0213, an NRG Oncology/GOG Study—Analysis of patient reported outcomes (PRO) on chemo
暂无分享,去创建一个
P. Sabbatini | Byoung-Gie Kim | R. Coleman | T. Herzog | K. Basen-Engquist | Joan L. Walker | D. Armstrong | D. O’Malley | K. Tewari | K. Fujiwara | Helen Q. Huang